{"id":"ctap101-capsules","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypercalcemia"},{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Calcitriol is the active metabolite of vitamin D that binds to the vitamin D receptor (VDR) in intestinal epithelial cells and bone, promoting calcium and phosphate absorption and homeostasis. This formulation is designed to treat secondary hyperparathyroidism and related mineral metabolism disorders in patients with chronic kidney disease or other conditions causing vitamin D deficiency.","oneSentence":"CTAP101 is a capsule formulation of calcitriol (active vitamin D) that enhances calcium absorption and regulates calcium-phosphate metabolism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:07.110Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Secondary hyperparathyroidism in patients with chronic kidney disease"},{"name":"Vitamin D deficiency-related mineral metabolism disorders"}]},"trialDetails":[{"nctId":"NCT07494045","phase":"PHASE2","title":"Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants","status":"NOT_YET_RECRUITING","sponsor":"OPKO Health, Inc.","startDate":"2026-06","conditions":"CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism","enrollment":40},{"nctId":"NCT05543928","phase":"PHASE3","title":"Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism","status":"TERMINATED","sponsor":"OPKO Health, Inc.","startDate":"2023-01-31","conditions":"Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Vitamin d Deficiency","enrollment":2},{"nctId":"NCT03602261","phase":"PHASE2","title":"Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI","status":"TERMINATED","sponsor":"OPKO Health, Inc.","startDate":"2018-07-09","conditions":"Secondary Hyperparathyroidism Due to Renal Causes, Chronic Kidney Diseases, Vitamin D Deficiency","enrollment":44},{"nctId":"NCT01651000","phase":"PHASE3","title":"Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency","status":"COMPLETED","sponsor":"OPKO IP Holdings II, Inc.","startDate":"2012-09","conditions":"Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency","enrollment":213},{"nctId":"NCT01704079","phase":"PHASE3","title":"Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency","status":"COMPLETED","sponsor":"OPKO IP Holdings II, Inc.","startDate":"2012-11","conditions":"Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency","enrollment":216},{"nctId":"NCT04551911","phase":"PHASE2","title":"Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19","status":"COMPLETED","sponsor":"OPKO Health, Inc.","startDate":"2020-11-02","conditions":"COVID-19, Coronavirus, SARS-CoV2 Infection","enrollment":171},{"nctId":"NCT03588884","phase":"PHASE4","title":"Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency","status":"COMPLETED","sponsor":"OPKO Health, Inc.","startDate":"2018-06-08","conditions":"Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency, CKD Stage 3","enrollment":69},{"nctId":"NCT03660800","phase":"PHASE1","title":"Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects","status":"COMPLETED","sponsor":"OPKO Health, Inc.","startDate":"2018-08-20","conditions":"Vitamin D Insufficiency, Secondary Hyperparathyroidism","enrollment":67},{"nctId":"NCT02274623","phase":"PHASE1","title":"Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid","status":"COMPLETED","sponsor":"OPKO Health, Inc.","startDate":"2014-12","conditions":"Breast Cancer, Prostate Cancer, Bone Neoplasms","enrollment":33},{"nctId":"NCT02282813","phase":"PHASE3","title":"Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002","status":"COMPLETED","sponsor":"OPKO Health, Inc.","startDate":"2013-04","conditions":"Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency","enrollment":298},{"nctId":"NCT01219855","phase":"PHASE2, PHASE3","title":"Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)","status":"COMPLETED","sponsor":"OPKO Health, Inc.","startDate":"2010-10","conditions":"Chronic Kidney Disease, Secondary Hyperparathyroidism, Vitamin D Insufficiency","enrollment":78},{"nctId":"NCT00888069","phase":"PHASE1","title":"Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects","status":"COMPLETED","sponsor":"OPKO IP Holdings II, Inc.","startDate":"2009-05","conditions":"Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":32203,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Calcifediol","calcifediol"],"phase":"phase_3","status":"active","brandName":"CTAP101 Capsules","genericName":"CTAP101 Capsules","companyName":"OPKO Health, Inc.","companyId":"opko-health-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CTAP101 is a capsule formulation of calcitriol (active vitamin D) that enhances calcium absorption and regulates calcium-phosphate metabolism. Used for Secondary hyperparathyroidism in patients with chronic kidney disease, Vitamin D deficiency-related mineral metabolism disorders.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}